AFFiRiS will explore ProBioGen's Human Artificial Lymph Node Technology for Vaccine Testing
AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for it…
AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for it…
The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's…
A recently approved project of the sixth EU Framework Programme – MimoVax – is focussing on a new target for an Alzheime…